Inactivated orf virus (ORFV, parapoxvirus ovis) induces antiviral activity in animal models of acute and chronic viral infections and exerts strong effects on human immune cells. ORFV activates antigen presenting cells (APC) via CD14 and, probably, Toll-like receptor signalling, and triggers the release of IFN-c that has been identified as the key mediator of the antiviral activity. After delineating virus proteins as being the most likely active constituent, we aimed to characterize the ORFV proteins responsible for the therapeutic effect. By using a vaccinia virus/ORFV expression library we identified several multi-gene DNA fragments with strong immunomodulatory activity. Together these fragments contain 27 ORFs. The encoded proteins are related to virion structure and transcription but are otherwise unrelated. Two proteins were separately expressed and purified, and demonstrated immunostimulatory activity. Gene expression profiles induced by ORFV and the identified fragments were investigated by microarray analysis. Interestingly, all active fragments induced a similar gene-expression pattern, differing only in quantitative aspects. Obviously, several proteins of ORFV activate similar cellular pathways, modulating APC to generate a strong T-helper 1-dominated immune response. This was balanced by additional induction of immune dampening mechanisms, suggesting regulatory differences compared to single cytokine therapies. We conclude that ORFV may have the potential to enrich the armamentarium of antiviral therapies.
INTRODUCTION
Parapoxvirus ovis (orf virus, ORFV) is a member of the family Poxviridae and causes a contagious skin disease in sheep and goats, but may also infect humans. Although a vigorous inflammatory immune response is observed after infection, the virus can repeatedly infect its host. Several immune-escape mechanisms have been identified, including a variety of captured cellular genes, e.g. a viral interleukin (IL)-10 homologue, a granulocyte macrophage colony-stimulating factor (GMCSP), an IL-2-inhibiting protein and the vaccinia E3L gene encoding an interferonresistance factor (Haig et al., 2002) . We recently demonstrated that the immunomodulatory properties of ORFV can be beneficially used to influence the clinical course of viral infections in experimental models (Weber et al., 2003) . A non-infectious preparation of inactivated ORFV induced strong antiviral activity in a guinea pig model of genital herpes disease, in a transgenic mouse model for human hepatitis B virus infection and in mice infected with human herpes simplex virus (Weber et al., 2003) . The protective effects of ORFV could be delineated to the induction of a T-helper 1 (T h 1)-dominated immune response with the release of IL-12, IL-18 and interferon (IFN)-c. IFN-c was identified as the key mediator of the antiviral activity as its neutralization abolished antiviral effects in vivo. The inflammatory response was limited by subsequent upregulation of T-helper 2 (T h 2) cytokines such as IL-4. In contrast to direct application of T h 1-inducing or effector cytokines (e.g. , no significant side effects were observed under these experimental conditions. Consistent with findings in in vivo animal models, we demonstrated that inactivated ORFV acts on human immune cells mediating the release of T h 1 cytokines IFN-c, IL-12 and IL-18, inflammatory cytokines TNF-a, IL-8 and IL-6, as well as anti-inflammatory cytokines such as IL-10, IL-1RA and the T h 2 cytokine IL-4 (Friebe et al., 2004) . Complement opsonization and probably an intracellular uptake of ORFV particles by macrophages are necessary for in vitro activity, and subsequent cellular signalling is mediated via CD14 and, most likely, a toll-like receptor (TLR) (Friebe et al., 2004) . Previous results further demonstrate that the immunomodulatory activity of inactivated ORFV is associated with the virus particles (Weber et al., 2003; Friebe et al., 2004) . Thus, active components could be delineated to either viral proteins, cellular proteins incorporated into the virus particles (e.g. in enveloped virions) or viral DNA. Also, viral proteins not present in virions but produced during early gene transcription have to be considered since inactivation methods might prevent infectivity but not necessarily early gene transcription. Based on these results, we aimed to more closely characterize the viral components that are relevant for the therapeutic effect by using a vaccinia virus (VACV) Lister/ORFV expression library. In a second step, we aimed to investigate gene expression patterns induced by ORFV and active ORFV fragments to determine the signalling pathways relevant for transducing the antiviral activity.
RESULTS

Proteins are necessary for ORFV-induced antiviral activity
Microbial DNA containing unmethylated CpG motifs can directly stimulate the immune system (Krieg, 2002) . Since ORFV has the highest guanine and cytosine (G+C) content among poxviruses (Wittek et al., 1979) , we wished to test whether isolated DNA of ORFV has immunomodulatory activity in mice infected with lethal doses of suid herpesvirus 1 (Aujeszky virus). Mice were pretreated with DNA of ORFV D1701, complete inactivated ORFV D1701, oligodeoxynucleotides (ODN) 1668 and 1826 containing unmethylated CpG motifs and PBS. ODNs and ORFV DNA were given in combination with incomplete Freund's adjuvant (IFA) to enhance endocytosis and intracellular uptake. Twenty-four hours after pre-treatment, mice were infected with Aujeszky virus and an efficacy index (EI) was calculated showing the percentage of mice that survived infection relative to the survival rate of a PBS pre-treated control group. x 2 Tests revealed significant differences between control and test groups for an EI¢60 %. Both ORFV and ODNs showed EI.60 %, whereas isolated DNA of ORFV had no protective effect (Fig. 1a) . However, this does not exclude involvement of DNA since we cannot be sure that isolated DNA emulsified in IFA was able to access the appropriate intracellular compartments.
In a subsequent experiment, we wished to test whether viral proteins are required for the beneficial effects of ORFV. For this purpose, ORFV D1701 was pre-treated with proteinase K and was tested for its antiviral activity in the Aujeszky mouse model. After treatment with proteinase K, only protein fragments with a molecular mass of ,16 kDa were detectable, whereas untreated ORFV preparations contain proteins between 250 and ,4 kDa (Fig. 1b) , thus verifying the successful proteolysis of the preparation. In the Aujeszky mouse model proteinase K treatment completely abrogated antiviral activity (Fig. 1c) , indicating that viral proteins are required either for directly mediating the antiviral activity or for mediating intracellular uptake of virus particles.
Next, we wished to compare ORFV preparations which had been inactivated by binary ethyleneimine (BEI) or by heat inactivation. BEI is known to alkylate nucleic acids, thereby significantly damaging DNA, but reacts very little with proteins (Groseil et al., 1995) . BEI and heat-inactivated ORFV preparations did not differ in their antiviral activity (Fig. 1d ). In addition, since heat inactivation over a period of 120 min would strongly reduce transcription activity (Harper et al., 1978 ) the involvement of early transcribed gene products seems unlikely.
Five recombinants of a VACV/ORFV expression library show immunomodulatory activity on human immune cells
To more closely identify active components, we used an ORFV strain NZ2 expression library that has been described by Mercer et al. (1997) . It consists of 16 recombinant VACVs containing overlapping genomic fragments of ORFV NZ2. The library represents 95 % of the whole ORFV genome and each fragment encodes several proteins. Whereas ORFV induces significant cytokine release by human immune cells, inactivated VACV has only minimal cytokine-inducing activity (Friebe et al., 2004 ). Thus, it was possible to screen the inactivated recombinant viruses for activity on human immune cells to determine which contained the active genome fragments of ORFV. Cell cultures were stimulated with the test substances and the level of release of TNF-a and IFN-c, the key mediators for the antiviral activity of ORFV in vivo (Weber et al., 2003) , were determined. As described recently (Friebe et al., 2004) , in vitro IFN-c induction by ORFV requires a second stimulus that is provided by a low dose of concanavalin A (ConA), which alone induces only minimal or no IFN-c but when given in combination with ORFV results in markedly enhanced cytokine secretion. In contrast, TNF-a is sufficiently induced without co-stimulation. Five ORFV NZ2 fragments (VVOV330, VVOV285, VVOV243, VVOV96 and VVOV97) showed clear TNF-a and IFN-c induction (Fig. 2a, b) . Stimulation with the active recombinants also showed that, if they were used at the same concentration, TNF-a induction was slightly lower while IFN-c induction was slightly higher than the induction observed for complete ORFV ( Supplementary Fig. S1 , available in JGV Online). To exclude the possibility of contamination of the test substances with lipopolysaccharide (LPS), we repeated the stimulation in the presence of bactericidal permeability increasing protein (BPI), which specifically blocks LPS activity (Elsbach & Weiss, 1993; Zhai et al., 2008) . BPI did not prevent TNF-a release by the test substances, thus excluding the possibility of contamination with LPS (Fig. 2c) .
Four VACV/ORFV recombinants induce antiviral activity in the Aujeszky mouse model
We first tested inactivated VACV for antiviral activity against Aujeszky virus infection. While ORFV NZ2 induced significant antiviral effects (EI¢60 %), VACV was not protective (Fig. 3a) . In a further step, we studied the VACV/ORFV recombinants in this mouse model. All recombinants were tested in three independent experiments, except for VVOV97 and VVOV243 which were tested in four experiments. Notably, these tests were performed with at least two independently prepared virus preparations. Only groups treated with VVOV215, VVOV245, VVOV285 and VVOV330 reached EIs with a Immune stimulatory components of inactivated orf virus mean .60 % (Fig. 3b) . However, several recombinants (all dosed at 10 8 TCID 50 ml 21 to ensure sufficient dosage of single ORFV fragments) showed EIs of approximately 40 %, suggesting some background activity, which might be due to the VACV backbone at this high concentration. As VACV and the inactive recombinants were grown on the same cell line, these results further exclude incorporated cellular proteins from being responsible for the immune stimulatory effects.
Characterization of ORFs located on the active ORFV NZ2 fragments
Five active recombinants were identified in the human in vitro system (VVOV330, VVOV285, VVOV243, VVOV96 and VVOV97) and four recombinants showed statistically significant antiviral activity in the Aujeszky mouse model (VVOV215, VVOV245, VVOV 285 and VVOV330). The immune stimulatory activity might be mediated either by the inserted DNA fragment or by the encoded proteins. We checked the percentage G+C content of active and inactive ORFV fragments. However, as the ORFV genome is relatively consistent in its G+C content (Mercer et al., 2006) , there was no evidence for a correlation between antiviral activity and G+C content (data not shown). However, this does not exclude other specific DNA sequences within the active fragments having effects. To identify ORFs located on the active fragments, a PCR of the terminal flanking regions of the inserts was performed. The integrated ORFV sequences were determined by comparison with the ORFV genome sequence (Mercer et al., 2006) . Table 1 gives an overview of the ORFs located on the overlapping active and inactive fragments. It also provides information about the putative function of the encoded gene products, either known for ORFV itself or based on sequence homologies with VACV Lister or molluscum contagiosum virus. ; recombinants, 10 6.2 -10 8.1 (see methods); and 8-16 mg ConA ml "1 as a co-stimulus. IFN-c is shown as ratio of (test substance+ConA)/(VACV+ConA). Absolute values for VACV+ConA are 7.0 IU ml "1 (donor 1), 4.0 IU ml "1 (donor 2) and 1.8 IU ml "1 (donor 3). Owing to the variability of donors in the response to ORFV (Friebe et al., 2004) , the results of single donors are displayed. (b) TNF-a induction in whole-blood cell cultures depicted as ratios of test substance/VACV. Absolute values for VACV are 67.7 pg ml "1 (donor 1), 83.1 pg ml "1 (donor 2) and 44.8 pg ml "1 (donor 3). (c) TNF-a induction by active recombinants in the presence of BPI (all viruses 10 4.6 TCID 50 ml "1 , 100 pg LPS ml "1 and 10 mg BPI ml
). TNF-a induction of each test substance in the absence of BPI was set to 100 % and results in the presence of BPI are shown as percentages of this value.
A. Friebe and others inactive fragments. Based on what has been shown for their VACV homologues (Resch et al., 2007) , 78 % of proteins located on the active fragments would be predicted to be in ORFV virions [intracellular mature virus (IMV) particles]. Of these proteins, 71 % are structural proteins, 24 % are involved in transcription and 5 % have unknown functions. From the 22 % of proteins that would not be predicted to be in ORFV virions, 50 % are related to transcription and 50 % have unknown functions. None of the VACV homologues that are known to be specifically located on enveloped virus particles was located on the active fragments.
The immunomodulatory activity of recombinant VVOV330 is mediated by the encoded proteins Recombinant VVOV330, which was active in the Aujeszky mouse model and on human immune cells, contains only two single ORFs (102 and 103) that are not present on surrounding inactive fragments ( Table 1 ). The N-termini of both gene products show homology with Atype inclusion-body (ATI) proteins of other poxviruses (e.g. A26L of VACV), while the C-terminal domain shows homology with viral fusion proteins (e.g. A27L of VACV). The ATI protein domains of ORFV ORFs 102 and 103 show 27 % homology, while the fusion protein domains show 18 % homology. Sequences of both proteins show distinct heterogeneity between poxviruses. The VACV homologues are located on intracellular mature virions (Resch et al., 2007) and the A27L gene product facilitates cell entry and release of enveloped virions by fusion of membranes (Rodriguez et al., 1987) . We generated recombinant VACVs containing single ORFV ORFs 102 and 103. Both recombinants significantly induced antiviral activity in the Aujeszky mouse model and stimulated IFN-c, but not TNF-a, release in human immune cells (Fig. 4a-c) . In a second step, purified recombinant proteins of ORFs 102 and 103 were generated by expression in baculovirus. Both proteins dissolved only with the addition of SDS (1 % final concentration), indicating that they were associated with cellular membranes ( Supplementary Fig. S2 , available in JGV Online). They were tested in the Aujeszky mouse model, and, if administered alone, none of the proteins had a protective effect, but when combined with inactive VACV, full antiviral activity was induced (Fig. 4d) . Furthermore we generated a VVOV recombinant containing a frameshift mutation of ORF 103, which showed significantly impaired antiviral activity (Fig. 4e-f ). These data demonstrate the immune stimulatory activity of at least two ORFV proteins.
Microarray analysis of gene expression profiles induced by ORFV and active recombinants
We wished to analyse gene expression profiles induced by VACV and by ORFV strains NZ2 and D1701. We also included recombinants with activity in the human test system (VVOV96, VVOV97, VVOV243, VVOV285 and VVOV330) as we assumed that this would allow matching of certain gene regulatory activity with certain genome fragments of ORFV. One inactive fragment, VVOV82, was included as a negative control. Mice were intraperitoneally (i.p.) injected with test substances and NaCl. Peritoneal cells, obtained 6 h after injection, were used for analysis of gene expression profiles. In a subsequent experiment, we briefly characterized these cells by flow cytometry. Approximately 70 % of peritoneal CD45 + leukocytes were Mac-1 + macrophages with no differences between groups. Staining with propidium iodide showed no increase in the percentage of dead cells after ORFV treatment, excluding apoptotic effects after ORFV application ( Supplementary Fig. S3 , available in JGV Online). , (a) and VVOV recombinants, all at 10 8 TCID 50 ml "1 (b). EIs ¢60 % are statistically significant (x 2 test). Recombinants were tested in at least three independent experiments and data are shown as mean EI±SD.
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On: Tue, 15 Jan 2019 20:09:07 ). Substances were tested in three independent experiments and data are shown as mean EI±SD. EIs ¢60 % are statistically significant (x 2 test). (b and c) IFN-c and TNF-a release by human whole-blood cell cultures stimulated with VVOV330, VACV and ORFs 102 and 103 expressed in VACV (all at 10 4.6 TCID 50 ml "1
). ConA (8-16 mg ml ) and purified proteins of ORF102 and ORF103 expressed in baculovirus with a C-terminal histidine tag [both 2.5 mg ml "1 ; other concentrations tested but not shown were 10 mg ml 
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For analysis of gene transcription, we used microarrays containing 648 cDNAs of genes involved in signal transduction, apoptosis, immunology, oncology, and cell-cell and cell-matrix adhesion. For the first query we compared gene expression patterns between NZ2 and D1701 versus VACV. Only genes that were detected in all three experiments were included in this analysis. Five genes (CCL3, IL15_1, CASP11_1, RASA4 and CCL5) were strongly upregulated by both ORFV strains and four genes (TGFB2, APRIL, ICAM2 and ITGA6) were strongly downregulated by ORFV strains but not by VACV (Fig. 5a ). In the second query we compared gene expression profiles of all active fragments, VVOV330, VVOV285, VVOV243, VVOV96 and VVOV97, versus the inactive fragment VVOV82, including only genes that were detected for the inactive fragment VVOV82 and for at least three of the active fragments (Fig. 5b) . Eight genes were strongly downregulated by the active fragments (ITGA6, TGFB2, FN1, ASC, TIMP2, APRIL, CCND1 and MAF1) and four genes were strongly upregulated (CCL3, CCL22, IL8RB_1 and GP9). In the third query we compared the two fragments with in vivo and in vitro activity (VVOV330 and VVOV285) with the in vivo inactive recombinants (VVOV243, VVOV96 and VVOV97). These two fragments mainly differed in suppression levels of APRIL, ITGA6, FN1, CXCL13 and THBS1 (Fig. 5c) . A brief summary of the gene products with respect to their putative involvement in transferring antiviral activity is given in Supplementary  Table S1 (available in JGV Online).
Interestingly, all active recombinants, but not the inactive fragment VVOV82, induced an expression pattern similar to complete ORFV. Differences in gene regulation between the fragments, but also between fragments and complete ORFV, were mainly quantitative, indicating that different fragments of ORFV induce/inhibit the transcription of similar genes relevant to the protective effects of ORFV.
DISCUSSION
The aims of the present work were firstly, to characterize the active constituents of ORFV particles responsible for immune regulatory effects and secondly, to investigate gene expression patterns induced by ORFV and its active fragments, as identified in step 1, to determine target genes and signalling pathways relevant for conferring the antiviral activity in responder cells.
With regard to the first aim above: for identifying immune regulatory ingredients of ORFV, preceding experiments had revealed that the immunomodulatory activity is associated with virus particles (Weber et al., 2003; Friebe et al., 2004) . Virus free supernatants from infected and non-infected cell cultures showed no immunostimulatory activity in the Aujeszky model and were inactive on human immune cells, excluding a soluble factor produced spontaneously or after viral infection by host cells or virus.
After centrifugation of the ORFV preparation (consisting of purified virus material) at only 4000 g, the immunoactive components were exclusively contained in the pellet, indicating that the activity is linked to virus particles. Thus, active components could be delineated to either viral proteins, cellular proteins incorporated in the virus particles (e.g. in enveloped virions since the ORFV preparation contains both enveloped and non-enveloped particles) and viral DNA. Also, viral proteins not present in virions but produced during early gene transcription have to be considered.
Here, we further demonstrate that proteins are required either for directly mediating the antiviral activity or for mediating the intracellular uptake of virus particles, since proteinase K treatment completely abrogated ORFV effects in vivo. A role for DNA could not be demonstrated by our experiments but is difficult to rule out completely. Cellular proteins incorporated in virus particles were excluded since VACV and inactive recombinants were grown on the same cell line and should therefore contain similar cellular proteins to the active recombinants. A role for early gene transcription seems unlikely as well since there was no difference between BEI and heat-inactivated virus preparations, which over 120 min are predicted to have strongly reduced transcriptional activities (Harper et al., 1978) .
Five recombinants were identified with activity on human immune cells (VVOV96, VVOV97, VVOV243, VVOV285 and VVOV330) and four with activity in the Aujeszky mouse model (VVOV215, VVOV245, VVOV285 and VVOV330). The immune-stimulatory activity of these recombinants might be mediated either by DNA fragments or by the encoded proteins. It has been shown that the live VVOV recombinant viruses express ORFV proteins during infection (Mercer et al., 1997) . Presence of ORFV proteins in purified inactivated particles has not been investigated, as there are only a limited number of mAbs available, especially against defined antigens. Proteins might be unspecifically incorporated in VACV virions, as has been shown for other proteins expressed by VACV (Gó mez & Esteban, 2001) . Specific incorporation into the particle in competition with a homologous VACV protein might also be a possibility but seems unlikely to be very common. Presence of soluble ORFV proteins in the preparations can be excluded since we used purified virus particles. Early gene transcription seems unlikely, but if it occurs this would also be the case for inactive recombinants, assuring us that, in any case, it is the ORFV insert which is mediating the activity. In this case the relevant ORFV protein would not be present in the virion but would be produced during early transcription. Twenty-seven ORFs were located exclusively on the active recombinants, which contained rather central sequences of the ORFV genome essential for virus replication, while the terminal region of ORFV included captured cellular genes that were part of stimulatory inactive recombinants. The encoded proteins are all related to virus structure and transcription and the majority would be present in ORFV virions, as predicted from their VACV homologues (Resch et al., 2007) . Since poxviruses are complex structures they might be easily recognized by innate immune mechanisms. While the active viruses possess immune evasion strategies (e.g. an IL-10 homologue), these mechanisms might be absent in inactivated ORFV. Thus, inactivated particles might trigger an antiviral immune response conferring protection against other viral infections. Consistent with this hypothesis, active fragments primarily contained parts of the ORFV genome encoding structural and transcription-related proteins.
For recombinant VVOV330, we could demonstrate that the immunomodulatory activity is mediated by the encoded proteins and not by its ORFV DNA fragment, since purified proteins of ORFs 102 and 103 induced antiviral effects when given in combination with inactive VACV and a frameshift mutation of VVOV ORF 103 showed significantly decreased activity. However, VACV particles were required either for delivering a co-stimulatory signal or for facilitating intracellular uptake. Consistently, complement factor C3 was shown to be necessary for IFN-c induction by ORFV (Friebe et al., 2004) , indicating that complement activation either mediates intracellular uptake or provides a co-stimulatory signal to macrophages to produce IL-12 in response to ORFV proteins. In contrast to VVOV330, the in vivo activities of VVOV ORFs 102 and 103 were not mirrored by in vitro TNF-a release, which was surprising since these are the only two ORFs completely present on VVOV330. Thus, either parts of ORF 101 (also present on VVOV330 but not on inactive VVOV283) are responsible for TNF-a induction or ORF 104/105 (also present on inactive VVOV85) have co-stimulatory effects in combination with ORF 102/103.
With regard to the second aim above: gene expression profiles in mouse peritoneal cells were analysed and the expression levels of nine genes (CCL3, IL15_1, CASP11_1, RASA4, CCL5, TGFB2, APRIL, ICAM2 and ITGA6) were strongly altered by ORFV NZ2 and ORFV D1701, in comparison with VACV. Twelve genes (ITGA6, TGFB2, FN1, ASC, TIMP2, APRIL, CCND1, MAF1, CCL3, CCL22, IL8RB_1 and GP9) were strongly regulated by the active fragments in comparison with the inactive fragment. The two fragments with in vitro and in vivo activities (VVOV330 and VVOV285) mainly differed in suppression levels of APRIL, ITGA6, FN1, CXCL13 and THBS1.
T h 1 induction seems to be a key mechanism for the antiviral activity of ORFV, as several of the most strongly suppressed genes are probably functioning in that way. Suppression of the immune inhibitory TGF-b system seems to be an important target as TGF-b is the gene that is most strongly suppressed by ORFV and all of the active fragments. Moreover, the in vivo active preparations (VVOV330, VVOV285, NZ2 and D1701) were additionally characterized by a marked suppression of thrombospondin 1 (THBS1), which is the main activator of TGF-b. TGF-b activity is mainly regulated by its activators as minimal amounts of active TGF-b induce a maximal cellular response. It acts as an immunosuppressive via T-cell inhibition and tolerance induction in antigen presenting cells (APC) by inhibiting IL-12 secretion (Annes et al., 2003; Schramm et al., 2004; Masli et al., 2006) . In addition, tolerance induction is markedly promoted by direct THBS1 signalling (Marteau et al., 2005; Masli et al., 2006) . ITGA6 (integrin a-6 chain), also significantly suppressed by ORFV, has been shown to bind to papilloma virus resulting in activation of phosphatidylinositol 3-kinase (PI3) pathways (Fothergill & McMillan, 2006) . This leads to negative regulatory feedback for early T h 1 polarization after TLR signalling because of reduced IL-12 release (Fukao & Koyasu, 2003) . PI3 activation has also been shown for polyomavirus, Epstein-Barr virus, cytomegalovirus and hepatitis B virus (Fothergill & McMillan, 2006) . By downregulation of ITGA6, ORFV enables macrophages/ APC to respond to subsequent infection with an enhanced T h 1 response. Additionally, downregulation of intercellular adhesion molecule 2, which also activates PI3 kinase pathways (Perez et al., 2002) might contribute to this effect. ORFV also strongly induced several genes that encode cytokines and chemokines with antiviral activity, such as CCL3, CASP11_1, CCL5, IL-8RB_1 (CXCR2) and IL-15. CCL3 supports an antiviral response by attracting NK cells and CD8 + effector T-cells (Glass et al., 2003; Trifilo & Lane, 2004) . Caspase-11 is essential for activation of interleukin-1b-converting enzyme and thus for production of IL-1 (Wang et al., 1998) . IL-15 is an antiviral key mediator that triggers T h 1 differentiation and activation/ maturation of NK cells and CD8
+ T-cells (Mastroianni et al., 2004; Alpdogan & van den Brink, 2005) . CCL5 is an inflammatory chemokine produced by virus-infected cells Only genes that were detected for the inactive fragment and for at least three of the active fragments were included in the analysis. (c) Comparison of gene expression profiles induced by the fragments VVOV330 and VVOV285 with in vitro and in vivo activity versus the in vivo inactive fragments VVOV243, VVOV96 and VVOV97 by PTM (correlation to template, 0.9). Only genes detected in all five hybridization experiments were included in the analysis.
Immune stimulatory components of inactivated orf virus and immune cells (Culley et al., 2006; Kumar et al., 2009) , and IL-8RB-1 (CXCR2) mediates cell migration in response to IL-8, a potent chemoattractant (Ben-Baruch et al., 1997) . T h 1 enhancement might be further supplemented by the inhibitory effects of ORFV on humoral Bcell responses. APRIL, which is strongly suppressed by ORFV, is involved in activation and differentiation of Bcells (Ng et al., 2005; Dillon et al., 2006) , and CXCL13, which is suppressed especially by the in vivo active fragments, is a major regulator of B-cell trafficking (Ansel et al., 2002) .
These results are consistent with previous findings showing strong T h 1 induction by ORFV in mice and human cell cultures (Weber et al., 2003; Friebe et al., 2004) . Interestingly, these effects are obtained by influencing multiple regulatory pathways in APC, indicating their dominance over single cytokine therapies (e.g. IL-12 and IFN-c). In addition, T h 1 enhancement is primarily achieved by downregulation of T h 1-suppressive pathways, resulting in increased T h 1 induction only in cases of concomitant or subsequent infection. This explains why in vitro stimulation with ORFV alone does not induce IFN-c while it is strongly increased with ConA co-stimulation.
Some genes modulated by ORFV seem to exert immune regulatory functions, e.g. ASC and CCL22. ASC is an intracellular adaptor protein involved in inflammatory response pathways and ASC knockout mice are resistant to LPS-induced endotoxic shock (Mariathasan et al., 2004; Johnston et al., 2005) . Thus, suppression of ASC protects against overwhelming immune responses, which is especially important in the context of its strong T h 1 promoting activity. Recently, a poxvirus protein (ORF M13L gene product) has been described that interacts with ASC to inhibit an inflammatory host response (Johnston et al., 2005) . CCL22 is a T-helper 2-cell (T h 2) attractant chemokine as its receptor is preferentially expressed on T h 2 and regulatory T-cells (Penna et al., 2002) . This is in line with previous results, demonstrating that the initial increase of T h 1 cytokines was followed by upregulation of IL-4. Thus, the T h 1-promoting activity of ORFV is balanced by the induction of immuneregulatory pathways protecting against overwhelming immune activation. This is supported by the absence of severe side effects in animals and humans after single therapeutic trials.
Interestingly, gene expression profiles revealed similar expression patterns for ORFV and active recombinants but not for the inactive fragment VVOV82. Differences in gene regulation were mainly quantitative. Since the antiviral activity of VVOV330 was mediated by encoded proteins, we assume that different proteins of ORFV might be able to activate similar cellular pathways that modulate APC to generate a strong T h 1-dominated response. These results highlight the potential of inactivated ORFV to enrich the armamentarium of antiviral therapies.
METHODS
Virus preparations. All viruses (ORFV NZ2, ORFV D1701, VACV Lister and recombinants) were grown and titrated on the bovine kidney cell line BK-KL 3A as described previously (Weber et al., 2003) . Virus preparations contain both enveloped and non-enveloped virions. For removal of cell debris, harvested virus was centrifuged (2000 g, 10 min), the supernatant filtered and concentrated by ultracentrifugation (30 000 g, 1 h ). Viruses were heat inactivated twice for 1 h at 58 uC. All viruses were purified, concentrated and inactivated in exactly the same manner. For comparison of BEI versus heat inactivation, ORFV D1701 was inactivated by BEI. Successful inactivation of viruses was confirmed by plaque titration on BK-KL 3A cells.
VACV/ORFV expression library. The library was described by Mercer et al. (1997) . It consists of 16 recombinant VACV Lister containing overlapping genomic fragments of ORFV NZ2 (5.3-18.1 kbp) representing 95 % of the whole genome. Expression of ORFV proteins was demonstrated by immunofluorescence and immunoprecipitation in live recombinants during infection. VACVs containing single ORFV ORFs and the frameshift mutation of ORF103 were prepared in the same way (Mercer et al., 1997) .
Human cell cultures. Heparinized blood was collected from healthy human donors after approval by the local ethics committee and after informed consent was provided by study participants. Blood was diluted 1 : 5 with Roswell Park Memorial Institute medium (RPMI 1640; Biochrom) containing 2 mM L-glutamine. Virus preparations were used in the experiment shown in Fig. 2(a, b) ; VVOV285, 10 6.7 and VVOV330, 10 6.2 . ConA (Serva) was used for co-stimulation as described previously (Friebe et al., 2004) at concentrations between 8 and 16 mg ml 21 . Other stimulants were 100 pg LPS ml 21 (Escherichia coli; Sigma) and 10 mg BPI ml 21 (Xoma).
ELISA tests. IFN-c EASIA (0.9-30 IU ml 21 ; Biosource), Immulite TNF-a assay (2-1000 pg ml 21 , DPC Biermann).
Aujeszky model. Female NMRI mice (Harlan, Borchen, Germany) were kept in a daily 12 h light-dark cycle with free access to food and water. Animal care and experiments were conducted according to institutional guidelines and after approval by the state authority for animal research conduct of North Rhine-Westphalia, Germany. Groups of mice (n510) were treated i.p. with test substances 24 h prior to challenge. In the first experiment (Fig. 1a) , mice were injected with 0.2 ml of ORFV D1701 (10 5.7 TCID 50 ml 21 ), negative control [mixture of 0.1 ml PBS (pH 7.4), 200 mg BSA, 0.1 ml IFA], ODN1668 (TCCATGACGTTCCTGATGCT; 0.01 mg and 0.1 mg), ODN1826 (TCCATGACGTTCCTGACGTT; 0.01 mg and 0.1 mg) and ORFV DNA (0.01 mg, 0.1 mg and 0.15 mg). ORFV DNA and ODNs were dissolved in a mixture containing 0.1 ml PBS, 200 mg BSA and 0.1 ml IFA. Besides the groups receiving test substances (n510), a control group (n510) was included that received pretreatment with PBS. Twenty-four hours after pre-treatment, mice were i.p. infected with 0.2 ml active Aujeszky virus (suid herpesvirus-1) strain Hannover H2 (10 4 TCID 50 ml 21 ), which is 10-20-fold greater than the LD 50 . Ten days after infection, the number of dead mice was compared between control and test groups by calculating an efficacy index (EI), which is defined as EI5(b2a)/ b6100 (b5number of dead mice in the control group; a5number of dead mice in the test group). Thus, the EI represents the percentage of mice that survived owing to pre-treatment with the IP: 54.70.40.11
On: Tue, 15 Jan 2019 20:09:07 test substance relative to the survival rate in the control group. x 2 Tests were used for statistical analyses (P,0.05 was taken to be significant) and an EI.60 % indicates significant differences between test and control groups. Some experiments were repeated to robustly discriminate between active and inactive antiviral test substances and in these cases mean EIs are displayed.
Regarding DNA isolation, proteinase K treatment, analysis of ORFs on active ORFV NZ2 inserts, protein expression in baculovirus, performance of microarray experiments and flow cytometric analysis, please see the Supplementary Methods for detailed methodology (available in JGV Online).
